Cardiac Radionuclide Imaging to Assess Patients With Heart Failure

Travin, Mark I.

doi:10.1053/j.semnuclmed.2014.04.005

Cited by 25 publications

(15 citation statements)

References 206 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, it can be challenging to evaluate 123 I-MIBG SPECT studies visually, especially in patients with HF and a global reduction in uptake (35). Automated quantitation of 123 I-MIBG SPECT studies offers the potential to overcome some of the limitations of visual image interpretation and improves the clinical utility of such studies for diagnosis and prognosis.…”

Section: Advances In 123 I-mibg Spect Quantitationmentioning

confidence: 99%

“…An analysis of the 123 I-MIBG SPECT studies from the AdreView Myocardial Imaging for Risk Evaluation in Heart Failure (ADMIRE-HF) trial, which is a prospective trial evaluating 123 I-MIBG imaging for identifying patients who have HF and are most likely to experience cardiac events, demonstrated that the SPECT HMR was equivalent to the planar HMR for discriminating between patients with HF and control subjects (6,34). Additionally, the ability of 123 I-MIBG SPECT to provide regional information not available on planar images remains a driver for efforts to incorporate this procedure into assessments of patients with HF for arrhythmic event risk (35).…”

Section: I-mibg Spect Complements Planar Imagingmentioning

confidence: 99%

See 1 more Smart Citation

¹²³I-MIBG SPECT for Evaluation of Patients with Heart Failure

2015

View full text Add to dashboard Cite

Heart failure (HF) is characterized by activation of the sympathetic cardiac nerves. The condition of cardiac sympathetic nerves can be evaluated by 123 I-metaiodobenzylguanidine ( 123 I-MIBG) imaging. Most cardiac 123 I-MIBG studies have relied on measurements from anterior planar images of the chest. However, it has become progressively more common to include SPECT imaging in clinical and research protocols. This review examines recent trends in 123 I-MIBG SPECT imaging and evidence that provides the basis for the increased use of the procedure in the clinical management of patients with HF. 123 I-MIBG SPECT has been shown to be complementary to planar imaging in patients with HF in studies of coronary artery disease after an acute myocardial infarction. Moreover, 123 I-MIBG SPECT has been used in numerous studies to document regional denervation for arrhythmic event risk assessment. For better quantification of the size and severity of innervation abnormalities in 123 I-MIBG SPECT, programs and protocols specifically for 123 I have been developed. Also, the introduction of new solid-state cameras has created the potential for more rapid SPECT acquisitions or a reduction in radiopharmaceutical activity. Although PET imaging has superior quantitative capabilities, 123 I-MIBG SPECT is, for the foreseeable future, the only widely available nuclear imaging method for assessing regional myocardial sympathetic innervation.

show abstract

Section: Advances In 123 I-mibg Spect Quantitationmentioning

confidence: 99%

Section: I-mibg Spect Complements Planar Imagingmentioning

confidence: 99%

¹²³I-MIBG SPECT for Evaluation of Patients with Heart Failure

2015

View full text Add to dashboard Cite

show abstract

“…The provision of accurate diagnosis of coronary artery disease is the main objective in the evaluation of various patient populations especially those with diabetes, hypertension, and others. Technical issues such as hybrid imaging and the study of myocardial viability and in some cases sympathetic innervations in patients with heart failure using 123I MIBG can add valuable information that could be useful for patient management [3].…”

mentioning

confidence: 99%

Metamorphosis of Nuclear Medicine

Loutfi¹

2015

Int J Radiol Med Imag

View full text Add to dashboard Cite

show abstract

“…The potential utility of assessing myocardial sympathetic neurons with nuclear imaging using the norepinephrine analog 123 I-metaiodobenzylguanidine ( 123 I-MIBG) (2,3) has been extensively evaluated as a prognostic indicator in HF patients (4)(5)(6)(7)(8). The largest prospective study to demonstrate prognostic significance for the planar heart-to-mediastinum ratio (H/M) in HF subjects was ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) (9).…”

mentioning

confidence: 99%

¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study

et al. 2015

View full text Add to dashboard Cite

ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) established the prognostic significance of 123 Imetaiodobenzylguanidine ( 123 I-MIBG) imaging in heart failure subjects (median follow-up, 17 mo) using a composite endpoint dominated by heart failure progression. The ADMIRE-HF extension (ADMIRE-HFX) extended follow-up to a median of 24 mo and used mortality as the primary endpoint. The objective of these analyses was to use multiple multivariate risk modeling techniques to determine the independent predictive ability of 123 I-MIBG imaging for mortality outcomes. Methods: Data from 964 New York Heart Association class II-III subjects in ADMIRE-HFX were included. All-cause mortality and a composite endpoint of death or death-equivalent events (resuscitated arrest, successful defibrillation for ventricular tachycardia or ventricular fibrillation) were analyzed with multivariate Cox proportional hazards and logistic regression techniques using demographic and clinical variables and the 123 I-MIBG heartto-mediastinum ratio (H/M). The incremental value of H/M was also examined for the logistic regression models using receiveroperating-characteristic curve methods and for the proportional hazards models using net reclassification improvement. Results: There were 101 deaths, and 136 subjects had a composite event during follow-up. H/M was significant in all multivariate proportional hazards and logistic regression models for the 2 mortality endpoints, both models developed with only clinical variables and those including left ventricular ejection fraction and b-type natriuretic peptide (BNP). For baseline models including BNP, the addition of H/M did not significantly increase receiver-operating-characteristic curve area. However, there was significant net reclassification improvement with the addition of H/M to a proportional hazards model containing BNP and left ventricular ejection fraction. Conclusion: The multivariate Cox proportional hazards and logistic regression analyses demonstrated consistent significance for H/M when added to the baseline risk models for mortality and mortality-equivalent events.

show abstract

Cardiac Radionuclide Imaging to Assess Patients With Heart Failure

Cited by 25 publications

References 206 publications

¹²³I-MIBG SPECT for Evaluation of Patients with Heart Failure

¹²³I-MIBG SPECT for Evaluation of Patients with Heart Failure

Metamorphosis of Nuclear Medicine

¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study

Contact Info

Product

Resources

About

Cardiac Radionuclide Imaging to Assess Patients With Heart Failure

Cited by 25 publications

References 206 publications

123I-MIBG SPECT for Evaluation of Patients with Heart Failure

123I-MIBG SPECT for Evaluation of Patients with Heart Failure

Metamorphosis of Nuclear Medicine

123I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study

Contact Info

Product

Resources

About

¹²³I-MIBG SPECT for Evaluation of Patients with Heart Failure

¹²³I-MIBG SPECT for Evaluation of Patients with Heart Failure

¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study